Neomycin

Synonym(s): Fradiomycin  |  Framycetin

Class: Aminoglycoside

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive and Gram-negative bacteria
Description:	Streptomyces natural product. Veterinary use, human use primarily for topical application and in combination
Institute where first reported:	Teva
Year first mentioned:	1947
Highest developmental phase:	Approved by FDA in 1964
Development status:	Approved, off-patent

Chemical structure(s):
Canonical SMILES:	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@@H](CN)O2)O)O)N)O[C@H]3[C@@H]([C@@H]([C@@H](CO)O3)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](CN)O4)O)O)N)O)O)N
Isomeric SMILES:	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
InChI:	InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
InChI Key:	PGBHMTALBVVCIT-VCIWKGPPSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/8378

External links:
Guide to Pharmacology:	neomycin
Main Source:	https://pubmed.ncbi.nlm.nih.gov/17782716/
Citation:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214720/